Verifying the Benefits of Radical Treatment in Posttransplant Hepatocellular Carcinoma Oligo‐recurrence: A Propensity Score Analysis. Issue 1 (16th November 2021)

• Record Type: Journal Article
• Authors: Au, Kin Pan; Fung, James Yan Yue; Dai, Wing Chiu; Chan, Albert Chi Yan; Lo, Chung Mau; Chok, Kenneth Siu Ho
• Is Part Of: Liver transplantation. Volume 28:Issue 1(2022)
• Page Start: 51
• Page End: 64
• Publication Date: 2021-11-16
• Subjects: Liver -- Transplantation -- Periodicals; Liver -- Diseases -- Periodicals; Liver Transplantation -- Periodicals; Foie -- Greffe -- Périodiques; 617.5560592
• DOI: 10.1002/lt.26251
• Languages: English
• ISSNs: 1527-6465

Abstract

Abstract : This study verified whether radical treatment for hepatocellular carcinoma (HCC) oligo‐recurrence after liver transplantation conveys survival benefits. A retrospective study of 144 patients with posttransplant HCC recurrence was performed. Propensity score matching was performed to adjust for baseline covariates between patients who received radical and palliative treatments. The primary endpoint was postrecurrence survival. A total of 50 patients (35%) received radical treatment for recurrence, and 76 (53%) and 18 (13%) patients received palliative and supportive treatments, respectively. Compared with the radical group, patients who received palliative treatment had more early recurrences (time from transplant 17 versus 11 months; P = 0.01) and more extensive disease in terms of tumor numbers (1 versus 4; P < 0.001), size of largest tumor (1.8 versus 2.5 cm; P = 0.046), numbers of involved organs (interquartile range [IQR], 1‐1 versus 1‐2; P = 0.02), and alpha‐fetoprotein (AFP) level (7 versus 40 ng/mL; P = 0.01). Multivariate Cox regression analysis revealed that early recurrence (time from transplant hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.01‐1.03; P = 0.001), larger recurrent tumor (HR, 1.12; 95% CI, 1.03‐1.23; P = 0.01), liver recurrence (HR, 1.84; 95% CI, 1.17‐2.90; P = 0.01), and log10 AFP level at recurrence (HR, 1.27; 95% CI, 1.07‐1.52; P = 0.01) predicted poor survival. Mammalian target of rapamycin inhibitor (HR, 0.331; 95% CI, 0.213‐0.548; P < 0.001) and radical treatment (HR, 0.342; 95% CI, 0.213‐0.548; P < 0.001) were associated with improved survival. After 2‐to‐1 propensity score matching for covariates, the 50 patients who received curative treatment survived significantly longer than the 25 matched patients who received palliative treatment (median survival time, 30.9 ± 2.4 versus 19.5 ± 3.0 months; P = 0.01). Radical treatment conveys survival benefits to HCC oligo‐recurrence after liver transplantation.